Next-Generation Bispecific Nanobody Targeting CD3 Complex and EGFR for Advanced Breast Cancer Therapy
VHH-P314 is a next-generation humanized nanobody therapeutic candidate directed against both CD3 Complex (T Cell Receptor Complex) and epidermal growth factor receptor (EGFR). Currently in the Biological Testing stage, this bispecific molecule is designed for targeted intervention in breast cancer. By integrating a compact nanobody format with precise specificity for EGFR and a functional anti-CD3 Fab, VHH-P314 seeks to harness immune effector cells while targeting malignancies characterized by EGFR expression. This innovative approach has the potential to address significant unmet needs in breast cancer treatment by enabling targeted immune redirection to tumor sites.
| Candidate | VHH-P314 |
| Target | CD3 Complex (T Cell Receptor Complex) epidermal growth factor receptor (EGFR) |
| Modality | humanized bispecific VHH |
| Indication | Breast Cancer |
Licensing Opportunity
VHH-P314 is a novel bispecific nanobody drug candidate open for partnering and licensing opportunities. We welcome inquiries from biopharmaceutical companies and academic collaborators seeking innovative solutions in breast cancer immunotherapy.
Contact UsDevelopment Phase
| Program | Research | Preclinical | Phase 1 |
|---|---|---|---|
| VHH-P314 |
Modality
VHH-P314 employs a bispecific T cell engager modality, incorporating an anti-EGFR nanobody with high tissue penetration and a robust stability profile due to its small, single-domain structure. The nanobody is conjugated via the Spycatcher system to an anti-CD3 Fab fragment, which is further fused to human serum albumin to improve half-life and pharmacokinetics. This design facilitates efficient tumor infiltration and sustained therapeutic activity. The dual engagement of EGFR-positive breast cancer cells and CD3-expressing T cells leads to targeted immune activation, offering advantages over conventional antibodies in overcoming the tumor microenvironment and delivering robust anti-tumor responses.
Target
CD3 Complex and EGFR are critical molecular targets in advanced oncology. CD3 Complex, a multi-subunit protein found on the surface of T cells, is pivotal for initiating and regulating immune responses. EGFR, a member of the ErbB family of receptors, is overexpressed in various epithelial malignancies, including subsets of breast cancer. While CD3 Complex is restricted to T cells, EGFR is predominantly observed on epithelial cells and is often upregulated in breast tumors, contributing to uncontrolled proliferation and survival. Targeting CD3 Complex facilitates immune cell engagement, while EGFR targeting allows selective tumor recognition. Co-targeting with VHH-P314 positions this bispecific molecule as a strategic asset for immuno-oncology pipelines, especially for breast cancer where EGFR is a validated but challenging target.
Mechanism of Action
VHH-P314 acts by concurrently binding to CD3 Complex on T cells and EGFR on tumor cells, functioning as a T cell engager and signal transduction modulator. This dual specificity recruits T cells to the vicinity of EGFR-expressing breast cancer cells, triggering T cell-mediated cytotoxicity upon synapse formation. The nanobody's modular architecture not only increases tumor specificity, but also minimizes off-target effects. Furthermore, the VHH platform provides future flexibility for derivative modalities such as antibody-drug conjugates or other bispecific immune cell engagers, broadening its therapeutic scope across oncology indications characterized by similar antigen profiles.
Breast Cancer
Breast cancer remains one of the most prevalent malignancies among women worldwide, with substantial morbidity and mortality. The disease is classified into multiple subtypes, often requiring personalized treatment regimens. Globally, its high incidence and mortality underline an urgent need for therapeutic innovation. Standard management includes surgery, chemotherapy, hormonal therapies, targeted interventions, and immunotherapies; however, resistance mechanisms, tumor heterogeneity, and recurrence present ongoing challenges. Limitations in existing therapies include off-target toxicity, limited penetration into solid tumors, and insufficient efficacy for specific subpopulations. VHH-P314 offers promise as a highly selective and versatile immunotherapeutic for breast cancer, particularly for patients with EGFR-expressing tumors, potentially addressing some of these unmet clinical needs through enhanced immune redirection and targeted cytotoxicity.